Results 11 to 20 of about 32,821 (278)

Bispecific antibodies and their applications [PDF]

Journal of Hematology & Oncology, 2015
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Mingju Hao, Zujian Wang, Gaowei Fan, Jinming Li   +3 more
openaire   +3 more sources

The making of bispecific antibodies [PDF]

mAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Ulrich Brinkmann, Roland E. Kontermann
openaire   +3 more sources

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Scientific Reports, 2021
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumor cells.
Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford, David J. DiLillo, Richard Tavaré, Erica Ullman, Shu Mao, Lauren Canova, Olga Sineshchekova, Jennifer Finney, Arpita Pawashe, Supriya Patel, Ryan McKay, Sahar Rizvi, Ermelinda Damko, Danica Chiu, Kristin Vazzana, Priyanka Ram, Katja Mohrs, Amanda D’Orvilliers, Jenny Xiao, Sosina Makonnen, Carlos Hickey, Cody Arnold, Jason Giurleo, Ya Ping Chen, Courtney Thwaites, Drew Dudgeon, Kevin Bray, Ashique Rafique, Tammy Huang, Frank Delfino, Aynur Hermann, Jessica R. Kirshner, Marc W. Retter, Robert Babb, Douglas MacDonald, Gang Chen, William C. Olson, Gavin Thurston, Samuel Davis, John C. Lin, Eric Smith   +43 more
doaj   +1 more source

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models

mAbs, 2020
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang, Jordan C. Tsai, Jonathan H. Davis, Bryant Chau, Jia Dong, Sean M. West, Jason M. Hogan, Matthew L. Wheeler, Christine Bee, Winse Morishige, Thomas Cayton, Donata David-brown, Chengyue Zhang, Alexander Kozhich, Tim Sproul, Gavin Dollinger, Arvind Rajpal, Pavel Strop   +17 more
doaj   +1 more source

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. [PDF]

, 2020
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response.
Chari, Ajai, Mezzi, Khalid, Scott, Emma, Shah, Nina, Usmani, Saad Z   +4 more
core   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources